Who Owns BTAI?

BioXcel Therapeutics, Inc. — Institutional Ownership & 13F Holdings

$1.06

-0.03 (-2.75%)

Market Cap

$29.5M

Shares Outstanding

27,074,586

Institutional Holders

30

Total Inst. Value

$809K

% of Float Held

1.8%

QoQ Holder Change

Institutional data as of Q1 2025

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1Murchinson Ltd.$276K136,076
2UBS Group AG$207K101,778
3GOLDMAN SACHS GROUP INC$50K24,794
4BlackRock, Inc.$47K23,241
5GEODE CAPITAL MANAGEMENT, LLC$44K22,062
6NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO$43K21
7Beacon Pointe Advisors, LLC$38K18,845
8VANGUARD GROUP INC$38K18,824
9WELLS FARGO & COMPANY/MN$25K12,293
10Virtu Financial LLC$22K10,666

Related Stocks

Frequently Asked Questions

How many institutional investors hold BTAI?

As of Q1 2025, 30 institutional investors report holding BTAI (BioXcel Therapeutics, Inc.) in their 13F filings.

What percentage of BioXcel Therapeutics, Inc. is owned by institutions?

Institutional investors hold approximately 1.8% of BioXcel Therapeutics, Inc.'s float as reported in SEC 13F filings.

Which hedge fund owns the most BTAI?

The largest institutional holder of BTAI is Murchinson Ltd. with $276K in shares.

Are institutions buying or selling BTAI?

This quarter, 30 institutions opened new positions in BTAI and 0 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.